Marizomib is a novel brain-penetrant pro­te­a­some inhibitor in devel­op­ment for patients with glioblastoma and re­lapsed and/or refractory multiple myeloma.

Toronto, ON and San Diego, CA (Press Release) – Triphase Accelerator Corpo­ra­tion, a private drug de­vel­op­ment com­pany dedicated to ad­vanc­ing novel com­­pounds through Phase 2 proof-of-concept, today an­nounced that Celgene Corpo­ra­tion, through an affiliate, has acquired the com­pany’s assets related to its pro­te­a­some inhibitor, marizomib (MRZ), which is in devel­op­ment for glioblastoma and re­lapsed and/or re­frac­tory multiple myeloma.

Under the terms of the agree­ment, Celgene will make an upfront payment plus addi­tional …

We're very glad to see you again, myeloma world.

Myeloma Morning was on brief hiatus while we helped with the Beacon's article about the recently published Ninlaro (ixazomib) clinical trial results.

Now that the Ninlaro article has been published, however, it's time to get back to normal Myeloma Morning business.

And there's a lot of it. In fact, there are almost 20 items in the list of new myeloma research at the end of today's report.

We obviously have to pace ourselves a …

Good morning, myeloma world.

After a particularly busy inaugural edition of Myeloma Morning, today's edition doesn't have quite as much ground to cover. We'll be focusing most of today's discussion on just four new research studies that have been published.

That being said, the first of those studies is going to require more than the usual amount of attention.

That's because the study is a new International Myeloma Working Group (IMWG) consensus state­ment concerning high-risk cytogenetics – a subject of significant interest to almost everyone in myeloma world (

-- Plenary Presentation at the 15th Inter­na­tional Myeloma Workshop --

Toronto, ON and San Diego, CA (Press Release) – Triphase Accelerator Corpo­ra­tion, a private drug de­vel­op­ment com­pany dedicated to ad­vanc­ing novel com­­pounds through Phase 2 proof-of-concept, today an­nounced pre­lim­i­nary results of a Phase 1 dose-escalation study of marizomib in com­bi­na­tion with poma­lido­mide (POM) and low dose dex­a­meth­a­sone (Lo-DEX) in patients with re­lapsed and refractory multiple myeloma. The marizomib/POM/Lo-DEX com­bi­na­tion was able to de­crease myeloma proteins by at least 50 per­cent to achieve an over­all response rate of 62 per­cent in …

-- Company Presenting Today at Biocom’s Global Life Science Partnering Conference --

Toronto and San Diego (Press Release) - Triphase Accelerator Corpo­ra­tion today announced that marizomib, its novel, potent pro­te­a­some inhibitor, has been granted orphan drug desig­na­tion by the U.S. Food and Drug Admin­istra­tion (FDA)'s Office of Orphan Products Development for the treat­ment of multiple myeloma. The orphan drug desig­na­tion will provide Triphase with 7-year market­ing exclusivity for marizomib and other benefits upon FDA approval.

“We are pleased that the FDA has granted orphan drug desig­na­tion for the de­vel­op­ment of …

In a recent review article pub­lished in the journal Clinical Cancer Re­search, two myeloma experts from the Dana-Farber Cancer In­sti­tute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treat­ment of mul­ti­ple myeloma.

In their article, the experts discuss newer ther­a­pies that appear to be promising in clin­i­cal and pre­clin­i­cal stud­ies.

According to the physicians, com­bi­na­tion ther­a­pies that spe­cif­i­cally target a patient’s ge­netic form of the dis­ease will be re­quired for long-term dis­ease con­trol and ultimately a cure.

Some Historical Perspective

In their review article, Drs. Munshi and …

Combined data from two recent Phase 1 clinical trials suggest that twice-weekly marizomib, with or without low-dose dexamethasone, may be effective for patients with relapsed or refractory multiple myeloma.

Dr. David Vesole from the John Theurer Cancer Center in Hackensack, New Jersey, who was not involved in the study, described marizomib as having “modest activity in relapsed/refractory myeloma.”

Dr. Paul Richardson from the Dana-Farber Cancer Institute in Boston presented the results at the American Society of Hematology (ASH) annual meeting in San Diego last month.

Marizomib (NPI-0052), which is being developed by …